SOP 410 - Duloxetine Extraction using Protein Precipitation for Quantification by Liquid Chromatography/Electrospray Mass Spectrometry/ Mass Spectrometry (LC/MS/MS)

Table of Contents

Uncontrolled Copy

SOP 410 - Duloxetine Extraction using Protein Precipitation for Quantification by Liquid Chromatography/Electrospray Mass Spectrometry/ Mass Spectrometry (LC/MS/MS)

SOP Name:		SOP #:
Duloxetine Extraction using Protein Precipitation for Quantification by Liquid Chromatography/Electrospray Mass Spectrometry/ Mass Spectrometry (LC/MS/MS)		**410**
North Carolina Office of the Chief Medical Examiner Toxicology Laboratory	**Revision:**	**Revision Date/Initials:**
	10.1.1.5 – Updated RT acceptance range 10.1.2.1 – Updated IRC acceptance range 10.1.3.2 – Updated Calibrator acceptance range 10.1.4.1 – Updated QC acceptance range 10.1.3.3 – Added reference to QA Manual (Cal point exclusion) 4 – Added standard prep instructions 6 – Updated instrument parameters	MSF – 05/08/2015 MSF – 04/04/2016 MSF – 05/25/2017 MSF – 06/05/2017

Approving Authority Name	Approving Authority Signature	Approval Date
Ruth E. Winecker, Ph.D.		04/17/2015
Ruth E. Winecker, Ph.D.		06/19/2016
Ruth E. Winecker, Ph.D.		12/07/2017

Uncontrolled Copy

SOP 410 - Duloxetine Extraction using Protein Precipitation for Quantification by Liquid Chromatography/Electrospray Mass Spectrometry/ Mass Spectrometry (LC/MS/MS)

1. **Principle of Assay**

1.1. This method is designed to confirm and quantitate duloxetine (Cymbalta) in biological specimens by Liquid Chromatography Tandem Electrospray Mass Spectrometry (LC/MS/MS). Duloxetine is extracted from biological matrices by protein precipitation with acetone and identified by the retention time and ion ratio of product ions. Duloxetine is subject to matrix effects, thus a stable isotopically labeled internal standard is used (1).

1.2. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), and as such blocks the reuptake of the neurotransmitters serotonin and norepinephrine. Insufficient amounts of these neurotransmitters have been associated with the pathophysiology of depression and other mental health disorders, thus blocking the reuptake of them increases their concentration in the synaptic cleft, diminishing depressive symptoms. (2)

Besides major depressive disorders, duloxetine is also approved for generalized anxiety disorder, neuropathic pain, fibromyalgia and musculoskeletal pain, as well as numerous "off-label" indications (3). Because of the large number of clinical indications for which duloxetine can be prescribed, in 2013 it was the fourth most prescribed drug in the United States (4), and likely to be detected in postmortem cases.

In this laboratory, screening for duloxetine is typically done in central blood specimens (*e.g.* aorta, inferior vena cava) via the organic bases screen (SOP 102). Duloxetine has a high volume of distribution (Vd ~20 L/kg) and is readily distributed in perfused organs such as the liver, lung, heart, and kidneys. Along with a high volume of distribution, duloxetine is also subject to postmortem redistribution (PMR), in which drugs diffuse from areas of high drug concentration, such as organ tissue, into the blood. Because of these two features, confirmation and quantitation of duloxetine is done in peripheral blood specimens (*e.g.* femoral, iliac) and liver, to more accurately reflect duloxetine concentration at the time of death and assist in interpretation. (5)

2. **Specimens**

2.1. This procedure is applicable to urine, blood, serum, *bile, *gastric contents, and properly prepared tissue specimens (typically 1:4 homogenates). A 0.1 mL (g) specimen amount (in duplicate) is generally employed unless a dilution is required so that the calibration curve encompasses the expected range of unknown specimens.

2.1.1. *For non-typical matrices, an additional 0.1mL aliquot shall be taken (volume permitting), spiked with appropriate QC, and analyzed to help to identify any matrix effects. (See Non-Matched Matrix Protocol section of the QA/QC manual).

Uncontrolled Copy

3. **Reagents and Materials**
   - 3.1. DI water, HPLC grade
   - 3.2. Methanol, HPLC grade
   - 3.3. Acetone, HPLC grade
   - 3.4. Acetonitrile, HPLC grade
   - 3.5. Deuterated Duloxetine Internal Standard Mix
   - 3.6. Duloxetine Standard
   - 3.7. Duloxetine e QC Standard (Standard & Control Worksheet)
   - 3.8. Drug Free Blood, Urine, Liver Homogenate
   - 3.9. Water with 0.1% formic acid
   - 3.10. Acetonitrile with 0.1% formic acid
   - 3.11. Methanol with 0.1% formic acid

4. **Standards, Controls, and Solutions**

   4.1. **Duloxetine-d3 Stock Solution (10µg/mL)**

   4.1.1. Into a 10mL volumetric flask, add the contents of 1 ampule (~1mL) of Duloxetine-d3 (Cerilliant – 100µg/mL).

   4.1.2. Fill to the line with methanol, insert stopper and invert three times to mix. Transfer to properly labeled 16x100mm screw topped test tubes and cap. Store in laboratory refrigerator (R1-2601). See SOP-010.

   4.2. **Duloxetine-d3 Internal Standard (1µg/mL)**

   4.2.1. Into a 10mL volumetric flask, add 1 ml of Duloxetine-d3 Stock Solution A (10µg/mL) with a micropipette.

   4.2.2. Fill to the line with methanol, insert stopper and invert three times to mix. Transfer to properly labeled 16x100mm screw topped test tubes and cap. Store in laboratory refrigerator (R1-2601). See SOP-010.

   4.3. **Duloxetine Calibrators and Positive Controls –** these standards are to be prepared by the QA/QC Chemist or appointee. Inform the QA/QC Chemist if calibration/control standards need to be made.

   4.4. **Water with 0.1% formic acid**

   4.4.1. To a 4L bottle of HPLC grade water, add 4 mL of formic acid

   4.4.2. Label bottle as “LC/MS” and “with 0.1% formic acid”.

Uncontrolled Copy

4.5. **Acetonitrile with 0.1% formic acid**

4.5.1. To a 4L bottle of HPLC grade acetonitrile, add 4 mL of formic acid

4.5.2. Label bottle as "LC/MS" and "with 0.1% formic acid".

4.6. **Methanol with 0.1% formic acid**

4.6.1. To a 4L bottle of HPLC grade methanol, add 4 mL of formic acid

4.6.2. Label bottle as "LC/MS" and "with 0.1% formic acid".

5. **Equipment and Special Supplies**
   - 5.1. Test Tubes, 13 x 100 mm
   - 5.2. LC autosampler vials, 12 x 32 mm
   - 5.3. Polyspring inserts, 5 mm O.D.
   - 5.4. Centrifuge 2000 x g
   - 5.5. Vortex mixer
   - 5.6. Nitrogen evaporator

6. **Instrumentation and Parameters**
   - 6.1. Windows PC with Thermo LCQuan and Xcaliber software
     - 6.1.1. Instrument method (TSQ02): "Duloxetine"
     - 6.1.2. Click here for instrument parameters.
   - 6.2. Thermo Surveyor LC autosampler, or equivalent
   - 6.3. Thermo Surveyor LC pump, or equivalent
   - 6.4. Thermo TSQ triple quadrupole mass spectrometer

7. **Target Ions** (± 1 nominal mass)

7.1.	Duloxetine	(**298**	154	44)
7.2.	Duloxetine -d6	(**301**	157	47)

7.2.1. Note: The precursor ion of each analyte is listed first and bolded, the first product ion- used for quantification-is second, followed by the second product ion-used for qualification/confirmation.

8. **Procedure**
   - 8.1. Prepare a colored tape label for each standard, blank, control, and specimen to be placed on 13x100 mm test tubes.
   - 8.2. Add the appropriate quantity (according to the Standard & Control Worksheet) of Deuterated Duloxetine Internal Standard Mix to all the tubes.
   - 8.3. Add the appropriate quantity (according to the Standard & Control Worksheet) of Duloxetine Standard and Duloxetine QC to the tubes labeled as standards

Uncontrolled Copy

and control, respectively, labeling test tubes as you go. Only internal standard should be present in the test tube labeled "Blank".

8.4. Add 0.1mL of blank blood to all standards, control, and blank test tubes (0.1 mL blank urine/0.1g blank liver homogenate to urine/liver blank and QC test tubes).

8.5. Add the appropriate amount of predetermined unknown specimen labeling test tubes as you go. (See Specimens section).

8.6. Vortex all test tubes for 10 seconds.

8.7. Add 3.5mL acetone to each tube and vortex for 20 seconds.

8.8. Centrifuge at 2000 x g for 10 minutes.

8.9. Decant the top acetone layer into clean and labeled 13x100 test tubes, place in nitrogen evaporator, and evaporate at 55° C to dryness.

8.10. Remove dried specimens from nitrogen evaporator and reconstitute with 500µL of methanol. Vortex for 10 seconds and centrifuge at 2000 x g for 5 minutes.

8.11. Transfer approximately 100µL of each extract to appropriately labeled autosampler vials fitted with 200 µL polyspring insert and place in the autosampler tray of the Thermo TSQ triple-quadrupole LC/MS/MS.

8.12. Build and initiate sequence as directed in SOP 053.

9. **Calculations**

9.1. Quantification

9.1.1. The method for processing the data using the Thermo LCQuan software is "Duloxetine" (SOP 055). It is used to calculate the internal standard response ratios, raw amounts, concentration, and ion ratios.

9.1.2. These calculations are computed as follows:

9.1.2.1. Response Ratio:

9.1.2.1.1. Response Ratio = response of the analytes quantifying product ion compared to that of the internal standard's quantifying product ion.

9.1.2.1.2. Response Ratio = QN_a / QN_{istd}

Uncontrolled Copy

9.1.2.1.2.1. QN_a = response of the quantitative ion of the analyte

9.1.2.1.2.2. QN_{istd} = response of the quantitative ion of the internal standard amount

9.2. Calibration

9.2.1. A linear regression resulting from the 6 standards is used to quantitate the analytes in the load. The area of the analyte divided by the area of the internal standard is used in the resulting formula of the calibration curve.

9.3. Dilution Factor

9.3.1. D = Total volume/Sample volume

9.4. Multiplier for homogenates, dilutions, and non-standard volumes

9.4.1. $M = (V_{curve} / V_{samp}) \times D$

9.4.1.1. M = Multiplier

9.4.1.2. D = dilution factor

9.4.1.3. V_{curve} = matrix volume of calibration curve

9.4.1.4. V_{samp} = matrix volume of specimen

9.5. Concentration

9.5.1. C = (A / V) * M

9.5.1.1. C = Concentration (ng/mL) of the analyte in the unknown case.

9.5.1.2. A = Amount of drug in sample

9.5.1.3. V = Volume of sample

9.5.1.4. M = Multiplier

9.6. Max/Min

9.6.1. Percent Difference = $((R_h / R_l)-1) \times 100$

9.6.1.1. R_h = high result

9.6.1.2. R_l = low result

9.7. Average

9.7.1. Average = $(R_1 + R_2) / 2$

9.7.1.1. R_1 = first result

9.7.1.2. R_2 = second result

9.8. Qualifier Ion Ratios

9.8.1.1.1. Ratio 1 = QL_1/QN

Uncontrolled Copy

9.8.2. QL_1 = response of the quantifying product ion

9.8.3. QN = response of the qualifying product ion

10. **Quality Control**

10.1. Acceptance criteria

10.1.1. Chromatogram

10.1.1.1. Peaks must be Gaussian shaped (symmetrical).

10.1.1.2. Peaks must not exhibit extreme fronting or tailing.

10.1.1.3. Peaks sharing parent/product ions must have baseline resolution.

10.1.1.4. The internal standard (ISTD) in each case should be inspected for evidence of signal enhancement and suppression. The area of the quantifying ion should not be less than 50% or more than 200% of the average ISTD of the calibrators.

10.1.1.5. Retention time must not deviate outside ± 3% of target, based upon the retention time of the calibrators and controls.

10.1.2. Mass spectroscopy

10.1.2.1. The ion ratio of all samples must not be greater than ± 20% of the target ratio, as determined by a mid-level calibrator (CAL 4).

10.1.2.2. Coelution of quantifying and qualifying ions must not be greater than 0.025 minutes.

10.1.3. Calibrators

10.1.3.1. Analytical curves must have a coefficient of determination (R^2) of 0.992 or greater.

10.1.3.2. Each calibrator, when calculated against the calibration curve, must not deviate outside ± 20% of the target value (± 25% at LOQ).

10.1.3.3. Refer to “Calibration curve point exclusion guidelines” section of the QA/QC Manual.

10.1.4. Controls

10.1.4.1. Controls must calculate within ± 20% of the target value.

10.1.5. Blanks

Uncontrolled Copy

10.1.5.1. Blanks should not contain any target analyte signal with an internal standard response ratio greater than 10% that of the lowest calibrator for the same analyte.

10.1.6. Any deviation from the above criteria must be approved by a senior chemist.

11. **Validation of Method**

Parameter	**Result**
Accuracy	**Blood - L:** 8.05% **H:** 9.87% **Liver - L:** 8.27% **H:** 11.01%
Precision	**Blood - L:** 1.30% **H:** 1.62% **Liver - L:** 2.79% **H:** 2.78%
Calibration model	Linear (1/x)
Carryover	Tested to 2X high calibrator with toxicologically insignificant amount of carryover. S/N threshold will be set to 999 - approximating calculated LOD (< 25% of low calibrator (0.04ug/mL)). Any peak with S/N < 999 will be considered "none detected".
Interference Studies	No interfering signal from matrix, internal standard, common drugs of abuse (including metabolites), OTC drugs, and Prescription medications observed
LOD (Calculate: 3.3xSD Y-intercept/Mean of Slope)	0.01 ug/mL
LOQ (Set to lowest calibrator with acceptable Accuracy/Precision).	0.02 ug/mL
Processed Sample Stability - (re-analyze after 3 & 8 days)	Extract stable for 7 days

Uncontrolled Copy

12. **Reporting**

12.1. The percent difference of duplicate analysis for an analyte must be less than or equal to 25% (see Max/Min in Calculations section).

12.2. Reporting of duplicate analysis should be done according to the table below:

Reporting Duplicates

- Dilution factors of 1 and 1

Dil / Scenario	1	1	REPORT
A	In curve	In curve	Average
B	In curve	AQL or BQL	"In" value
C	In curve	ND *	Repeat
D	AQL/BQL	AQL/BQL	Less than/ Greater than
E	BQL	ND	ND

* ND = None Detected, due to IRC, S/N threshold, r.t., or other

12.2.1.1. In Curve = Measured concentration (pre-multiplier) falls within the calibration range

12.2.1.2. AQL = Measured concentration (pre-multiplier) falls Above Quantitation Limit

12.2.1.3. BQL = Measured concentration (pre-multiplier) falls Below Quantitation Limit

12.2.1.4. ND = None Detected

12.3. Averaging reportable values

12.3.1. Results for duplicate analysis (both falling within calibration curve) shall be truncated prior to averaging.

12.3.2. Enter calculated concentration for each specimen into toxlog.

Uncontrolled Copy

12.4. Significant figures

12.4.1. Concentrations are truncated and reported with two significant figures in milligrams per liter (mg/L).

13. **Preparation of Load**

13.1. The load paperwork and data is to be arranged in the following order:

13.1.1. Assignment sheet

13.1.2. Comments or note to file if applicable

13.1.3. Load summary

13.1.4. Specimen worklist

13.1.5. Chain of custody (Specimen)

13.1.6. Aliquot chain of custody

13.1.7. Standard and control worksheet

13.1.8. Sequence summaries/calibration reports – paper clipped

13.1.9. Calibrator data - paper clipped

13.1.10. Blank matrix data - paper clipped

13.1.11. Control data - paper clipped

13.1.12. Specimen data – stapled

14. **References**

14.1. Chambers, Erin, Diane M. Wagrowski-Diehl, Ziling Lu, and Jeffrey R. Mazzeo. "Systematic and Comprehensive Strategy for Reducing Matrix Effects in LC/MS/MS Analyses." Journal of Chromatography B 852.1-2 (2007): 22-34.

14.2. Goodnick, P.J., Goldstein, B.J. “Selective serotonin reuptake inhibitors in affective disorders – I. Basic pharmacology.” *Journal of Psychopharmacology* (1998): S5-S20.

14.3. “Prescribing Information and Patient Package Insert: Cymbalta.” Lilly Medical

14.4. "Top 100 Most Prescribed, Top-Selling Drugs (2013)." MedScape Medical News. 01 Aug. 2014.

14.5. Anderson, D., S. Reed, J. Lintemoot, S. Kegler, S. Dequintana, M. Sandberg, and J. Muto. "A First Look at Duloxetine (Cymbalta(R)) in a Postmortem Laboratory." Journal of Analytical Toxicology 30.8 (2006): 576-80.

Uncontrolled Copy